Novartis AG

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CH0012005267
CHF
105.50
-0.48 (-0.45%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.98 M

Shareholding (Mar 2024)

FII

0.08%

Held by 15 FIIs

DII

99.92%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor long term growth as Net Sales has grown by an annual rate of -0.09% over the last 5 years

 
2

With ROE of 39.74%, it has a Very Expensive valuation with a 6.58 Price to Book Value

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CHF 224,339 Million ()

stock-summary
P/E

17.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.29

stock-summary
Return on Equity

36.86%

stock-summary
Price to Book

6.36

Revenue and Profits:
Net Sales:
11,608 Million
(Quarterly Results - Jun 2025)
Net Profit:
3,324 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
6.73%
0%
6.73%
6 Months
7.58%
0%
7.58%
1 Year
19.8%
0%
19.8%
2 Years
22.77%
0%
22.77%
3 Years
31.06%
0%
31.06%
4 Years
49.09%
0%
49.09%
5 Years
36.48%
0%
36.48%

Novartis AG for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-0.09%
EBIT Growth (5y)
9.15%
EBIT to Interest (avg)
14.48
Debt to EBITDA (avg)
0.60
Net Debt to Equity (avg)
0.59
Sales to Capital Employed (avg)
0.60
Tax Ratio
13.85%
Dividend Payout Ratio
67.17%
Pledged Shares
0
Institutional Holding
0.06%
ROCE (avg)
19.87%
ROE (avg)
25.50%
Valuation key factors
Factor
Value
P/E Ratio
17
Industry P/E
Price to Book Value
6.58
EV to EBIT
16.13
EV to EBITDA
11.99
EV to Capital Employed
4.55
EV to Sales
5.18
PEG Ratio
0.97
Dividend Yield
NA
ROCE (Latest)
28.21%
ROE (Latest)
39.74%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Bullish
Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 15 Foreign Institutions (0.08%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -2.42% vs 3.08% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 2.44% vs 31.12% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "11,608.20",
          "val2": "11,896.10",
          "chgp": "-2.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "4,822.00",
          "val2": "5,153.80",
          "chgp": "-6.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "238.70",
          "val2": "242.70",
          "chgp": "-1.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-296.50",
          "val2": "-44.00",
          "chgp": "-573.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "3,323.70",
          "val2": "3,244.40",
          "chgp": "2.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "332.90%",
          "val2": "346.30%",
          "chgp": "-1.34%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 8.52% vs 1.30% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 36.49% vs 33.34% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "44,312.50",
          "val2": "40,834.70",
          "chgp": "8.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "18,930.80",
          "val2": "18,102.40",
          "chgp": "4.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "913.30",
          "val2": "784.50",
          "chgp": "16.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1,696.20",
          "val2": "-3,236.90",
          "chgp": "47.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "10,514.30",
          "val2": "7,703.20",
          "chgp": "36.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "306.60%",
          "val2": "261.20%",
          "chgp": "4.54%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
11,608.20
11,896.10
-2.42%
Operating Profit (PBDIT) excl Other Income
4,822.00
5,153.80
-6.44%
Interest
238.70
242.70
-1.65%
Exceptional Items
-296.50
-44.00
-573.86%
Consolidate Net Profit
3,323.70
3,244.40
2.44%
Operating Profit Margin (Excl OI)
332.90%
346.30%
-1.34%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is -2.42% vs 3.08% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 2.44% vs 31.12% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
44,312.50
40,834.70
8.52%
Operating Profit (PBDIT) excl Other Income
18,930.80
18,102.40
4.58%
Interest
913.30
784.50
16.42%
Exceptional Items
-1,696.20
-3,236.90
47.60%
Consolidate Net Profit
10,514.30
7,703.20
36.49%
Operating Profit Margin (Excl OI)
306.60%
261.20%
4.54%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 8.52% vs 1.30% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 36.49% vs 33.34% in Dec 2023

stock-summaryCompany CV
About Novartis AG stock-summary
stock-summary
Novartis AG
Pharmaceuticals & Biotechnology
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Company Coordinates stock-summary
Company Details
Lichtstrasse 35 , BASEL None : 4056
stock-summary
Tel: 41 61 3241111
stock-summary
Registrar Details